![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sage’s and Biogen’s Tremors Drug Shows Promise in Phase 2 Study
Sage’s and Biogen’s Tremors Drug Shows Promise in Phase 2 Study
![Positive Results](https://www.fdanews.com/ext/resources/test/Drug-Images4/Postitive-Results.gif?t=1623701844&width=430)
Sage Therapeutics and Biogen have released positive topline results from a mid-stage study evaluating SAGE-324 as a treatment for individuals with essential tremor, a nervous system disorder that causes involuntary and rhythmic shaking.
The results, which included data from 67 participants, showed the drug reduced upper-limb tremor amplitude by 36 percent at day 29, vs. 21 percent for patients given a placebo.
Patients initially received a 60-mg dose, but this was reduced to a 45-mg or 30-mg dose if the drug wasn’t well-tolerated. Dose reduction occurred in 62 percent of participants with 38 percent of those receiving the drug having to discontinue its use, the companies said.
Upcoming Events
-
21Oct